Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00824720 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of a Glaucoma Drug Delivery System
A Phase 2 study of Ocular Hypertension and Glaucoma Open-Angle, sponsored by Vistakon Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 55
- Enrollment target
- 4
- Study locations
NCT00824720 is a Phase 2 study of Ocular Hypertension and Glaucoma Open-Angle that has completed, run by Vistakon Pharmaceuticals. The registered enrollment target is 55 participants, below the 277-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (80% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT00824720, a Phase 2 study of Ocular Hypertension and Glaucoma Open-Angle, has completed, sponsored by Vistakon Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 55 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to evaluate the ocular safety and efficacy of a glaucoma drug delivery system in open-angle glaucoma or ocular hypertension.
Conditions Studied
Interventions
- DEVICE Placebo Device
- DRUG High Dose Device
- DRUG Low Dose Device
Study Locations (4)
California
- - Artesia
Kentucky
- - Louisville
Maryland
- - Baltimore
South Carolina
- - Mt. Pleasant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2008-12 |
| Est. Completion | 2009-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00824720
The ClinicalTrials.gov registry entry for NCT00824720 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 277-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (80% lower). The listed sponsor is Vistakon Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Ocular Hypertension appearing as the primary indexed condition, and to 3 interventions - of which Placebo Device is the first listed.
NCT00824720 reports 4 study locations spanning 4 distinct geographic areas - top geographies include California, Kentucky, Maryland.
Frequently Asked Questions
What is clinical trial NCT00824720 about?
NCT00824720 is a clinical study titled "Safety and Efficacy of a Glaucoma Drug Delivery System". The purpose of this study is to evaluate the ocular safety and efficacy of a glaucoma drug delivery system in open-angle glaucoma or ocular hypertension.
What is the current status of trial NCT00824720?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 55 participants. The study started on 2008-12. Estimated completion is 2009-04.
What conditions does trial NCT00824720 study?
This clinical trial studies the following conditions: Ocular Hypertension, Glaucoma Open-Angle.
What interventions are being tested in trial NCT00824720?
The interventions under investigation include: Placebo Device (DEVICE), High Dose Device (DRUG), Low Dose Device (DRUG).
Who is sponsoring clinical trial NCT00824720?
This trial is sponsored by Vistakon Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00824720 being conducted?
This trial has 4 study locations across California, Kentucky, Maryland, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ocular Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluate Efficacy and Safety of PA5108 Ocular Implants in Primary Open Angle Glaucoma or Ocular Hypertension
RECRUITING · Phase 2
-
Travoprost Five Day Posology Study
COMPLETED · Phase 2
-
Multiple Dose-escalation Study of AMA0076 in Patients With Ocular Hypertension or Primary Open-angle Glaucoma
COMPLETED · Phase 2
-
Dose-Finding Study Comparing the Safety and Efficacy of Latanoprost to a Novel Treatment for Glaucoma
COMPLETED · Phase 2
-
A Safety and Efficacy Study of Fixed-Combination Bimatoprost and Brimonidine in Chronic Glaucoma or Ocular Hypertension
COMPLETED · Phase 2
-
Study to Assess the Efficacy, Safety and Tolerability of AKB-9778 Ophthalmic Solution as and Adjunct to Latanoprost in Patients With Ocular Hypertension or Open Angle Glaucoma
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.